Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMASS: Allogeneic ASCs for Dry Eye in Sjögren's Syndrome
NCT04615455Phase 2Completed
- Sponsor
- Rigshospitalet
- Start
- Nov 2020
- Primary completion
- Dec 2022
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in dry eye disease (DED) comparing ASCs with Placebo (2 arms). Primary endpoint: Ocular Surface Disease Index at 4 months. Started Nov 2020; status: completed.
02
Drugs
CSCC_ASC
03
Conditions
dry eye disease (DED)
Beyond the preview
Go deeper on NCT04615455.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04615455.